Stroke is a leading cause of death and long-term disability worldwide, and many patients remain at risk for recurrent events. At Johnson & Johnson, we are committed to advancing new approaches in stroke prevention, focused on better protecting patients without increasing their risk of bleeding.
J&J’s approach to stroke
Through the Librexia STROKE trial, part of the broader Librexia program, we are evaluating an investigational oral Factor XIa inhibitor, for its potential to reduce the risk of recurrent stroke or high-risk transient ischemic attack (TIA), while aiming to preserve hemostasis.
As part of one of the most comprehensive FXIa development programs to date, our work in stroke reflects a commitment to developing therapies that address real-world challenges in stroke prevention, especially for patients who are underserved or undertreated due to bleeding concerns.
We are investigating a new class of anticoagulants that may deliver reduced thrombotic events with less bleeding for more patients.”
